MYO News and Press, Myomo Inc. From 02/17/22

Brings the total number of patents issued on the MyoPro® device globally to 20 Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering fr...

Adds to Body of Evidence Supporting the Utility of MyoPro in Stroke and Traumatic Brain Injury Patients Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality fo...

Presentation Times and Weblinks Released for Over 70 Presenting Companies Wednesday and Thursday, January 19 th -20 th , 2022 NEW YORK, NY / ACCESSWIRE / January 18, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Small...

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’...

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today provided an update on reimbursement for it...

Company Continues to Innovate with Digital Technologies Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders an...

Receipt of Full License Fee and Technology Transfer Expected to Begin before March 31, 2022 Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those sufferin...

Myomo has a great deal of similarities in business strategy to its technological & industry peers in terms of markets, joint ventures, and insurance reimbursements. However, its cash position is much weaker, and will quite likely need to raise additional capital before the end of&...

Earnings Release Myomo, Inc. (NYSE American: MYO)  was featured in a company-sponsored research note published by Sidoti & Company, LLC. The headline of the note reads, “Myomo’s 3Q:21 Results Exceed Our Estimates; Estimate Expanded Reimbursement Will Fuel 30%-40% ...

Myomo, Inc. (MYO) Q3 2021 Results Conference Call November 10, 2021 04:30 PM ET Company Participants Kim Golodetz - LHA IR Paul Gudonis - CEO Dave Henry - CFO Conference Call Participants Ben Haynor - Alliance Global Partners Edward Woo - Ascendiant Capital Jim Sidoti - Sidoti & Company P...